COMMUNIQUÉS West-GlobeNewswire

Results Announced from Two Renal Denervation Studies at EuroPCR Show Positive Outcomes in High-Risk Hypertensive Patients
22/05/2019
Late-Breaking Clinical Trial Results and Updated Global SYMPLICITY Registry Data Demonstrate Long-Term Results of RDN for Uncontrolled Hypertension DUBLIN and PARIS - May 22, 2019 - Investigators today unveiled late- [...]
Nexstim sells first NBT® system in Germany for depression therapy and research
22/05/2019
Press release, Helsinki, 22 May 2019 at 11.30 am (EET) Nexstim sells first NBT ® system in Germany for depression therapy and research Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing [...]
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
22/05/2019
COPENHAGEN, Denmark, May 22, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the initiation of a new share buy-back program, under which the Company intends to buy back up to 28,849 of its own shares [...]
Centauri's AlphamerTM Platform highlighted at 4th Annual Advances in Immuno-Oncology Congress
22/05/2019
Centauri's Alphamer TM Platform highlighted at 4th Annual Advances in Immuno-Oncology Congress UK, 22 May 2019: Centauri Therapeutics (“Centauri”), an immunotherapy company active in oncology and infectious diseases, [...]
Motif Bio to Evaluate Orphan Disease Opportunity for Iclaprim in Ophthalmology
22/05/2019
NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an [...]
Bavarian Nordic Announces Interim Results for the First Three Months of 2019
22/05/2019
COPENHAGEN, Denmark, May 22, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results and business progress for the first three months of 2019. Paul Chaplin, President & Chief [...]
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
22/05/2019
New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled corticosteroid - LABA [...]
VALNEVA Reports Further Positive Results for Its Chikungunya Vaccine Candidate
22/05/2019
Valneva Reports Further Positive Results for Its Chikungunya Vaccine Candidate Phase 1 unblinded results up to month 7 showed an excellent immunogenicity and safety profile confirming Valneva's unique, single-shot [...]
VALNEVA annonce de nouveaux résultats positifs pour son candidat vaccin contre le chikungunya
22/05/2019
Valneva annonce de nouveaux résultats positifs pour son candidat vaccin contre le chikungunya Les résultats de Phase 1 obtenus dans les différents groupes vaccinés jusqu'au 7 e mois inclus montrent un excellent profil d [...]
argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day
22/05/2019
Expands pipeline with ARGX-117 and ARGX-118; two new pipeline candidates from its Innovative Access Program addressing first-in-class targets Highlights formation of two global therapeutic franchises in neuromuscular [...]
Sentia Medical Sciences Inc. Awarded Approximately $1.8 million Phase II Small Business Innovation Research (SBIR) Grant to Develop Astressins for the Treatment of Irritable Bowel Syndrome (IBS)
22/05/2019
SAN DIEGO, May 22, 2019 (GLOBE NEWSWIRE) -- Sentia announced today that it has been awarded a phase II small business innovation research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney [...]
Sorrento Therapeutics to Present at 20th Annual B. Riley FBR Investor Conference in Los Angeles (ca).
22/05/2019
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will be participating in the upcoming FB Riley Investor Conference [...]
MediPharm Labs Australia Awarded Cannabis Manufacturing Licence From Office of Drug Control – Establishes Asia-Pacific Foothold
21/05/2019
TORONTO, May 21, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a leader in specialized, research-driven cannabis extraction and cannabinoid [...]
Blinded Independent Validation Study Highlights Effectiveness of Tissue Systems Pathology Test in Predicting Risk of Progression to Esophageal Cancer in Patients with Barrett's Esophagus
21/05/2019
Data Presented at DDW 2019 Demonstrate Test Potential to Identify Patients Who May Benefit from Increased Surveillance and Early Therapeutic Intervention PITTSBURGH, PA, May 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE [...]
Syneos Health to Present at Upcoming Investor Conferences
21/05/2019
MORRISVILLE, N.C., May 21, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract [...]
Abattis Announces Successful Closing of Pro Natura Acquisition
21/05/2019
VANCOUVER, British Columbia, May 21, 2019 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “ Company " or " Abattis ") (CSE:ATT) (OTC:ATTBF) is pleased to announce that, further to its news release dated April 2 nd , [...]
MediPharm Labs Australia Awarded Cannabis Manufacturing Licence From Office of Drug Control – Establishes Asia-Pacific Foothold
21/05/2019
TORONTO, May 21, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a leader in specialized, research-driven cannabis extraction and cannabinoid [...]
ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
21/05/2019
RAMSEY, N.J. and BOCA RATON, Fla., May 21, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company [...]
Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
21/05/2019
NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that it will be presenting pharmacokinetic analyses of TNX-102 SL* in a poster at the [...]

Pages